Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure.

MLA

Oliveros, Estefania, et al. “Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure.” Cardiorenal Medicine, vol. 10, no. 2, 2020, pp. 69–84. EBSCOhost, https://doi.org/10.1159/000504167.

APA

Oliveros, E., Oni, E. T., Shahzad, A., Kluger, A. Y., Lo, K. B., Rangaswami, J., & McCullough, P. A. (2020). Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure. Cardiorenal Medicine, 10(2), 69–84. https://doi.org/10.1159/000504167

Chicago

Oliveros, Estefania, Ebenezer T Oni, Anum Shahzad, Aaron Y Kluger, Kevin Bryan Lo, Janani Rangaswami, and Peter A McCullough. 2020. “Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure.” Cardiorenal Medicine 10 (2): 69–84. doi:10.1159/000504167.